Current Illinois CancerCare Clinical Trials

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations (Temporarily Closed)

Study Number: EA5162 (Temporarily Closed)

Study Summary:
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Status: Suspended

Study Coordinator(s)
  • Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
  • Amanda , 309-243-3663, amullery@illinoiscancercare.com
  • Jessica, 309-243-3615, jjones@illinoiscancercare.com

Study Link

« Search Again